KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBITDA (2016 - 2025)

Edwards Lifesciences has reported EBITDA over the past 17 years, most recently at $151.1 million for Q4 2025.

  • Quarterly results put EBITDA at $151.1 million for Q4 2025, down 51.66% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 8.3% YoY), and the annual figure for FY2025 was $1.3 billion, down 8.3%.
  • EBITDA for Q4 2025 was $151.1 million at Edwards Lifesciences, down from $307.1 million in the prior quarter.
  • Over the last five years, EBITDA for EW hit a ceiling of $542.1 million in Q2 2021 and a floor of $151.1 million in Q4 2025.
  • Median EBITDA over the past 5 years was $370.4 million (2021), compared with a mean of $359.8 million.
  • Biggest five-year swings in EBITDA: skyrocketed 419.45% in 2021 and later tumbled 51.66% in 2025.
  • Edwards Lifesciences' EBITDA stood at $374.4 million in 2021, then crashed by 47.2% to $197.7 million in 2022, then skyrocketed by 75.42% to $346.8 million in 2023, then fell by 9.86% to $312.6 million in 2024, then tumbled by 51.66% to $151.1 million in 2025.
  • The last three reported values for EBITDA were $151.1 million (Q4 2025), $307.1 million (Q3 2025), and $411.2 million (Q2 2025) per Business Quant data.